Potaba

Miscellaneous Dietary Supplements

 Administer with a full glass of water or milk after meals or snacks. There are no specific foods to avoid, but a normal dietary intake should be maintained.

fever / Early / Incidence not known
rash / Early / Incidence not known
nausea / Early / Incidence not known
anorexia / Delayed / Incidence not known
vomiting / Early / Incidence not known

Potaba

Rx

Oral antifibrotic agent possibly effective for scleroderma, dermatomyositis, morphea, linear scleroderma, pemphigus, and Peyronie's disease
Potassium salt of para-aminobenzoic acid (PABA)
Available since before 1938

12 g/day PO is the average dose administered in 4—6 divided doses with meals and at bedtime with a snack. For patients with dermatomyositis, higher doses of 15—20 g/day may be required.

1 gram/day PO in divided doses for each 10 pounds of body weight. Give with meals and at bedtime with a snack.

Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.

Specific guidelines for dosage adjustments in renal impairment are not available. Aminobenzoate potassium is renally excreted and dosage adjustments may be required.

There are no drug interactions associated with Aminobenzoate Potassium products.

20 grams per day PO has been well tolerated in certain patients.

20 grams per day PO has been well tolerated in certain patients.

20 grams per day PO has been well tolerated in certain patients.

1 gram per day PO.

Safety and efficacy have not been established.

Safety and efficacy have not been established.

Aminobenzoate potassium is considered to be a member of the vitamin B complex family. The mechanism by which it exerts antifibrotic effects is not known. It has been suggested that the antifibrosis action is due to its mediation of increased oxygen uptake at the tissue level. Fibrosis is believed to occur from either too much serotonin or too little monoamine oxidase activity over a period of time. Monoamine oxidase (MAO) requires an adequate supply of oxygen to function properly. By increasing oxygen supply at the tissue level, aminobenzoate potassium may enhance MAO activity and prevent or bring about regression of fibrosis.

Aminobenzoate potassium is administered orally. It is considered a member of the B vitamin complex family and metabolism is similar to that seen with food. Excretion is through renal function.

Aminobenzoate potassium is considered a member of the B vitamin complex family and, thus, absorption is similar to that seen with food.

An FDA pregnancy risk category classification is not available for aminobenzoate potassium. According to the manufacturer, safe and effective use during pregnancy has not been established.

According to the manufacturer, safe and effective use during breast-feeding has not been established. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.